Syndax Pharmaceuticals Inc. (SNDX)’s Financial Results Comparing With EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)

This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership in Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals Inc. 8 0.00 18.98M -2.11 0.00
EyePoint Pharmaceuticals Inc. 1 0.00 60.25M -0.56 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 has Syndax Pharmaceuticals Inc. and EyePoint Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals Inc. 225,415,676.96% -110.2% -70.2%
EyePoint Pharmaceuticals Inc. 4,032,258,064.52% -228.1% -70.2%

Volatility & Risk

Syndax Pharmaceuticals Inc. is 130.00% more volatile than S&P 500 because the stock has a beta of 2.3. EyePoint Pharmaceuticals Inc.’s 63.00% more volatile than S&P 500 volatility due to the stock’s 1.63 beta.


Syndax Pharmaceuticals Inc.’s Current Ratio is 4.1 while its Quick Ratio is 4.1. On the competitive side is, EyePoint Pharmaceuticals Inc. which has a 4.5 Current Ratio and a 4.3 Quick Ratio. EyePoint Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Syndax Pharmaceuticals Inc.

Analyst Ratings

In next table is delivered Syndax Pharmaceuticals Inc. and EyePoint Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Syndax Pharmaceuticals Inc. 0 0 1 3.00
EyePoint Pharmaceuticals Inc. 0 0 2 3.00

The upside potential is 96.08% for Syndax Pharmaceuticals Inc. with consensus target price of $17. Competitively the consensus target price of EyePoint Pharmaceuticals Inc. is $4, which is potential 145.40% upside. The information presented earlier suggests that EyePoint Pharmaceuticals Inc. looks more robust than Syndax Pharmaceuticals Inc. as far as analyst opinion.

Institutional & Insider Ownership

Syndax Pharmaceuticals Inc. and EyePoint Pharmaceuticals Inc. has shares held by institutional investors as follows: 73.3% and 57.1%. Insiders held 0.1% of Syndax Pharmaceuticals Inc. shares. Comparatively, EyePoint Pharmaceuticals Inc. has 0.8% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Syndax Pharmaceuticals Inc. 19.34% 24.46% -1.36% 10.41% 82.77% 95.51%
EyePoint Pharmaceuticals Inc. -2.6% -35.06% -3.23% 2.04% -31.19% -20.63%

For the past year Syndax Pharmaceuticals Inc. has 95.51% stronger performance while EyePoint Pharmaceuticals Inc. has -20.63% weaker performance.


EyePoint Pharmaceuticals Inc. beats on 6 of the 9 factors Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.